RATIONALE, DESIGN AND ORGANIZATION OF AN EFFICACY AND SAFETY STUDY OF OXYPURINOL ADDED TO STANDARD THERAPY IN PATIENTS WITH NYHA CLASS III – IV CONGESTIVE HEART FAILURE

FREUDENBERGER, R.S., SCHWARZ, R.P., BROWN, J., MOORE, A., MANN, D., GIVERTZ, M.M., COLUCCI, W.S., & HARE, J.M.. (2004). RATIONALE, DESIGN AND ORGANIZATION OF AN EFFICACY AND SAFETY STUDY OF OXYPURINOL ADDED TO STANDARD THERAPY IN PATIENTS WITH NYHA CLASS III – IV CONGESTIVE HEART FAILURE. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 13(-), 1509-1516. SID. https://sid.ir/paper/541612/en

FREUDENBERGER R.S., SCHWARZ R.P., BROWN J., MOORE A., MANN D., GIVERTZ M.M., COLUCCI W.S., HARE J.M.. RATIONALE, DESIGN AND ORGANIZATION OF AN EFFICACY AND SAFETY STUDY OF OXYPURINOL ADDED TO STANDARD THERAPY IN PATIENTS WITH NYHA CLASS III – IV CONGESTIVE HEART FAILURE. EXPERT OPINION ON INVESTIGATIONAL DRUGS[Internet]. 2004;13(-):1509-1516. Available from: https://sid.ir/paper/541612/en

R.S. FREUDENBERGER, R.P. SCHWARZ, J. BROWN, A. MOORE, D. MANN, M.M. GIVERTZ, W.S. COLUCCI, and J.M. HARE, “RATIONALE, DESIGN AND ORGANIZATION OF AN EFFICACY AND SAFETY STUDY OF OXYPURINOL ADDED TO STANDARD THERAPY IN PATIENTS WITH NYHA CLASS III – IV CONGESTIVE HEART FAILURE,” EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 13, no. -, pp. 1509–1516, 2004, [Online]. Available: https://sid.ir/paper/541612/en